Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
Research Watch

Targeting JAG1 Sensitizes Bone Metastases to Chemotherapy

DOI: 10.1158/2159-8290.CD-RW2017-239
  • Article
  • Info & Metrics
Loading
  • Major finding: Chemotherapy induces JAG1 expression in osteoblasts, promoting chemoresistance in bone metastases.

  • Concept: A JAG1 antibody sensitizes breast cancer bone metastases to chemotherapy with minimal toxicity.

  • Impact: JAG1 may be a therapeutic target to prevent or reduce bone metastases in patients with breast cancer.


Embedded Image

Bone metastasis occurs in the majority of patients with late-stage breast cancer. The bone-forming osteoblast cells are essential for creating an osteogenic niche that allows for the survival and colonization of disseminated tumor cells in the bone. Expression of the Notch ligands jagged1 (JAG1) and NOTCH1 on breast cancer cells is associated with a poor prognosis, and JAG1 has been shown to promote bone metastasis by activating Notch signaling in osteoblasts and osteoclasts. However, attempts to target Notch signaling with γ-secretase inhibitors caused severe toxicity, preventing their further clinical development to treat bone metastasis. Zheng, Bae, and colleagues developed a fully humanized monoclonal antibody against JAG1 (15D11) to potentially limit the toxicity of Notch inhibition by targeting a single Notch ligand. 15D11 effectively blocked JAG1 and downstream Notch signaling with minimal toxicity in vivo. In a breast cancer bone metastasis xenograft model, 15D11 suppressed bone metastasis of JAG1-expressing tumor cells and synergized with chemotherapy to further reduce bone metastases. Mechanistically, chemotherapy induced JAG1 expression in osteoblastic cells (via induction of reactive oxygen species), which promoted the seeding and outgrowth of metastatic tumor cells in the bone. Coculturing tumor cells with osteoblasts protected against chemotherapy-induced apoptosis, and this chemoprotection could be reversed by 15D11. Interactions with osteoblast lineage cells protected JAG1-expressing tumor cells in the bone from chemotherapy, inducing chemoresistance. Thus, targeting JAG1 sensitized bone metastases to chemotherapy. In a mouse model of breast cancer with spontaneous bone metastasis, 15D11 treatment reduced the incidence of bone metastases in combination with chemotherapy. Consistent with these findings, in patients with breast cancer JAG1 was initially expressed at low levels on osteoblasts and upregulated following chemotherapy. Altogether, these findings suggest that JAG1 targeting may be beneficial in preventing and treating breast cancer bone metastases in combination with chemotherapy. Further, the safety profile of the anti-JAG1 antibody 15D11 supports its further clinical development.

Zheng H, Bae Y, Kasimir-Bauer S, Tang R, Chen J, Ren G, et al. Therapeutic antibody targeting tumor- and osteoblastic niche-derived jagged1 sensitizes bone metastasis to chemotherapy. Cancer Cell 2017;32:731–47.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2017 American Association for Cancer Research.
View Abstract
Next
Back to top

Published OnlineFirst December 21, 2017
doi: 10.1158/2159-8290.CD-RW2017-239

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Targeting JAG1 Sensitizes Bone Metastases to Chemotherapy
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
Citation Tools
Targeting JAG1 Sensitizes Bone Metastases to Chemotherapy
Cancer Discov December 21 2017 DOI: 10.1158/2159-8290.CD-RW2017-239

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Targeting JAG1 Sensitizes Bone Metastases to Chemotherapy
Cancer Discov December 21 2017 DOI: 10.1158/2159-8290.CD-RW2017-239
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • SLAM-seq Identifies Direct Transcriptional Targets of BRD4 and MYC
  • The IL15 Superagonist ALT-803 plus Nivolumab Has Antitumor Activity
  • Glioblastoma Stem Cell–Tumor Cell Cross-talk Drives Gliomagenesis
Show more Research Watch
  • Home
  • Alerts
  • Feedback
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement